Rivaroxaban vs Apixaban: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0111 | 0.0106 | 0.0116 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0104 | 0.00993 | 0.0109 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.000667 | -0.0000122 | 0.00135 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.06 | 0.999 | 1.13 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.06 | 0.999 | 1.14 | log | ClinicalTrials.gov | |
| Number needed to harm, for one more death from any cause on Rivaroxaban than on Apixaban | 1,500 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Rivaroxaban | Reference group~Rivaroxaban: Any rivaroxaban dispensing claim is used as the reference group | 1,958 | 176,990 | EG000 | ClinicalTrials.gov |
| Group 2 | Apixaban | Exposure group~Apixaban: Any apixaban dispensing claim is used as the exposure group | 1,840 | 176,990 | EG001 | ClinicalTrials.gov |
Harm 2
| Field | Value | Source |
|---|---|---|
| What it counts | Total, all-cause mortality | ClinicalTrials.gov |
| Time frame | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data | ClinicalTrials.gov |
| NCT number | NCT05256797 | ClinicalTrials.gov |
| Phases | ClinicalTrials.gov | |
| Conditions | Atrial Fibrillation | ClinicalTrials.gov |
| Interventions | Rivaroxaban, Apixaban | ClinicalTrials.gov |
| Lead sponsor | Brigham and Women's Hospital | ClinicalTrials.gov |
| Results first posted | 2025-03-04 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT05256797?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.